Effects of Fufang Tengli Decoction drug-containing serum on proliferation, apoptosis and epithelial-mesenchymal transition of human glioma U251 cells

doi:10.11958/20221840

Abstract

Abstract:

Objective To explore effects of Fufang Tengli Decoction drug-containing serum on the proliferation, apoptosis and epithelial-mesenchymal transition (EMT) of human glioma U251 cells. Methods A total of 24 male SD rats were divided into the control group, the low-dose, medium-dose and high-dose Fufang Tengli Decoction groups [6, 12, 24 g/(kg·d)], 6 rats in each group. After 10 d of continuous intragastric administration, blood samples was collected to prepare drug-containing serum, and human glioma U251 cells were treated for 24 h. The cells activity was detected by Cell Counting Kit-8. The cell cloning was detected by colony formation assay. The distribution of cells cycles and apoptosis were detected by flow cytometry. The expressions of proto-oncogene C-myc and cyclin D1 (CyclinD1) genes were detected by quantitative polymerase chain reaction. The expressions of B-cell lymphoma-2 (Bcl-2), Bcl-2 associated X protein (Bax), cysteine aspartase-3 (caspase-3), caspase-8, β-catenin, epithelial cadherin (E-cadherin) and vimentin (Vimentin) were detected by Western blot assay. Results The drug-containing serum with 10% volume fraction was selected as the final dose. Compared with the control group, cells activity, number of clone formation and expression levels of C-myc, CyclinD1 mRNA and Vimentin were decreased, while numbers of cells in S phase and expression levels of Bax/Bcl-2 and Caspase-3 were increased in the low-dose, medium-dose and high-dose Fufang Tengli Decoction groups (P<0.05). The proportion of cells in G2 phase and expression level of β-catenin were decreased, while expression levels of Caspase-8 and E-cadherin were increased in the medium-dose and high-dose Fufang Tengli Decoction groups (P<0.05). Cell apoptosis rate was increased in the high-dose Fufang Tengli Decoction group (P<0.05). Conclusion Fufang Tengli Decoction drug-containing serum can block human glioma U251 cells in S phase, inhibit cell proliferation, induce apoptosis, regulate expressions of β-catenin, E-cadherin and Vimentin, and inhibit EMT.

Key words: glioma, epithelial-mesenchymal transition, cell proliferation, apoptosis, cell proliferation inhibitors (TCD), Fufang Tengli Decoction, human glioma U251 cells

CLC Number:

R739.41

Figures/Tables 9

References 23

[1]	BAGLEY S J, KOTHARI S, RAHMAN R, et al. Glioblastoma clinical trials:current landscape and opportunities for improvement[J]. Clin Cancer Res, 2022, 28(4):594-602. doi:10.1158/1078-0432.CCR-21-2750.
[2]	DE BIASE G, GARCIA D P, BOHNEN A, et al. Perioperative management of patients with glioblastoma[J]. Neurosurg Clin N Am, 2021, 32(1):1-8. doi:10.1016/j.nec.2020.09.005.
[3]	LE RHUN E, PREUSSER M, ROTH P, et al. Molecular targeted therapy of glioblastoma[J]. Cancer Treat Rev, 2019, 80:101896. doi:10.1016/j.ctrv.2019.101896.
[4]	张悦, 刘爱迪, 范旭东, 等. 中药靶向递送系统治疗脑胶质瘤研究进展[J]. 中草药, 2021, 52(17):5358-5368.
	ZHANG Y, LIU A D, FAN X D, et al. Research progress of Chinese materia medica targeted delivery system in the treatment of glioma[J]. Chin Tradit Herb Drugs, 2021, 52(17):5358-5368. doi:10.7501/j.issn.0253-2670.2021.17.028.
[5]	滕舒慧, 周梦婕, 于冰清, 等. 中药活性成分抗脑胶质瘤的作用机制及相应新剂型研究进展[J]. 中国药房, 2021, 32(23):2934-2940.
	TENG S H, ZHOU M J, YU B Q, et al. Action mechanism of TCM active components against glioma and research progress of the corresponding new formulation[J]. China Pharm, 2021, 32(23):2934-2940. doi:10.6039/j.issn.1001-0408.2021.23.21.
[6]	何本求, 刘莉, 张芳, 等. 复方藤梨汤对结直肠癌术后化疗不良反应及临床疗效的观察[J]. 中医临床研究, 2021, 13(19):13-15.
	HE B Q, LIU L, ZHANG F, et al. Observation on clinical effcacy of the Fufang Tengli decoction on postoperative chemotherapy for colorectal cancer and adverse reaction[J]. Clin J Chin Med, 2021, 13(19):13-15. doi:10.3969/j.issn.1674-7860.2021.19.003.
[7]	陈奇. 中药药理研究方法学[M]. 3版. 北京: 人民卫生出版社, 2011:1261-1264.
	CHEN Q. Research methodology of TCM pharmacology[M]. 3rd ed. Beijing: People's Medical Publishing House, 2011:1261-1264.
[8]	李军, 唐东昕, 王镜辉, 等. 基于数据挖掘分析国医大师刘尚义治疗卵巢癌用药特点与规律[J]. 辽宁中医杂志, 2020, 47(4):42-46.
	LI J, TANG D X, WANG J H, et al. Medication characteristics and rules in the treatment of ovarian cancer based on data mining analysis by TCM master Liu Shangyi[J]. Liaoning J Tradit Chin Med, 2020, 47(4):42-46. doi:10.13192/j.issn.1000-1719.2020.04.011.
[9]	甘椿椿, 金湛, 魏晓鹏, 等. 藤梨根化学成分及其体外抗肿瘤转移活性[J]. 中成药, 2021, 43(2):403-407.
	GAN C C, JIN Z, WEI X P, et al. Chemical constituents from Actinidia chinensis and their antitumor metastatic activity in vitro[J]. Chin Tradit Pat Med, 2021, 43(2):403-407. doi:10.3969/j.issn.1001-1528.2021.02.020.
[10]	曹刘荐, 赖象权, 何本求, 等. 复方藤梨汤对结直肠癌术后化疗患者生存质量及免疫功能的影响[J]. 中华肿瘤防治杂志, 2020, 27(S1):104-105.
	CAO L J, LAI X Q, HE B Q, et al. Effects of Fufang Tengli decoction on quality of life and immune function in patients with colorectal cancer undergoing postoperative chemotherappy[J]. Chin J Cancer Prev Treat, 2020, 27(S1):104-105.
[11]	ZHANG G, ZHU Q, FU G, et al. TRIP13 promotes the cell proliferation,migration and invasion of glioblastoma through the FBXW7/c-MYC axis[J]. Br J Cancer, 2019, 21(12):1069-1078. doi:10.1038/s41416-019-0633-0.
[12]	DEHGHANI-SOLTANI S, EFTEKHAR-VAGHEFI S H, BABAEE A, et al. Pulsed and discontinuous electromagnetic field exposure decreases temozolomide resistance in glioblastoma by modulating the expression of O6-methylguanine-DNA methyltransferase,Cyclin-D1,and p53[J]. Cancer Biother Radiopharm, 2021, 36(7):579-587. doi:10.1089/cbr.2020.3851.
[13]	SIGHEL D, NOTARANGELO M, AIBARA S, et al. Inhibition of mitochondrial translation suppresses glioblastoma stem cell growth[J]. Cell Rep, 2021, 35(4):109024. doi:10.1016/j.celrep.2021.109024.
[14]	KANTARJIAN H M, HUGHES T P, LARSON R A, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase:ENESTnd 10-year analysis[J]. Leukemia, 2021, 35(2):440-453. doi:10.1038/s41375-020-01111-2.
[15]	GOLLA C, BILAL M, DWUCET A, et al. Photodynamic therapy combined with Bcl-2/Bcl-xL inhibition increases the Noxa/Mcl-1 ratio independent of Usp9X and synergistically enhances apoptosis in glioblastoma[J]. Cancers (Basel), 2021, 13(16):4123. doi:10.3390/cancers13164123.
[16]	ASHFAQUE A, HANIF F, SIMJEE S U, et al. Opuntiol inhibits growth and induces apoptosis in human glioblastoma cells by upregulating active Caspase 3 expression[J]. Asian Pac J Cancer Prev, 2021, 22(11):3607-3613. doi:10.31557/APJCP.2021.22.11.3607.
[17]	杨誉佳, 陆远富, 安强, 等. 藤梨根提取物对宫颈癌的抑制作用[J]. 中华中医药学刊, 2019, 37(7):1710-1714.
	YANG Y J, LU Y F, AN Q, et al. Inhibition of Actinidia Arguta extract on cervical cancer[J]. Chin Arch Tradit Chin Med, 2019, 37(7):1710-1714.
[18]	SU X, YANG Y, GUO C, et al. NOX4-derived ROS mediates TGF-β1-Induced metabolic reprogramming during epithelial-mesenchymal transition through the PI3K/AKT/HIF-1α pathway in glioblastoma[J]. Oxid Med Cell Longev, 2021, 2021:5549047. doi:10.1155/2021/5549047.
[19]	詹雯静, 梁铭杰, 刘媛, 等. STAT3抑制剂及烟酰胺联合用药对肝癌HepG2细胞增殖的抑制作用及机制研究[J]. 天津医药, 2022, 50(7):686-692.
	ZHAN W J, LIANG M J, LIU Y, et al. Effects and mechanism of STAT3 inhibitor and nicotinamide combination on the inhibiting proliferation of hepatocarcinoma HepG2 cells[J]. Tianjin Med J, 2022, 50(7):686-692. doi:10.11958/20212609.
[20]	DJEDIAI S, GONZALEZ SUAREZ N, EL CHEIKH-HUSSEIN L, et al. MT1-MMP cooperates with TGF-β receptor-mediated signaling to trigger SNAIL and induce epithelial-to-mesenchymal-like transition in U87 glioblastoma cell[J]. Int J Mol Sci, 2021, 22(23):13006. doi:10.3390/ijms222313006.
[21]	BABU D, MUDIRAJ A, YADAV N, et al. Rabeprazole has efficacy per se and reduces resistance to temozolomide in glioma via EMT inhibition[J]. Cell Oncol (Dordr), 2021, 44(4):889-905. doi:10.1007/s13402-021-00609-w.
[22]	LIU F, XU X H, LI C Y, et al. Rapid tumor recurrence in a novel murine GBM surgical model is associated with Akt/PD-L1/vimentin signaling[J]. Biochem Biophys Res Commun, 2021, 569:1-9. doi:10.1016/j.bbrc.2021.06.072.
[23]	吴幸冬, 唐德才. 黄芪配伍莪术对小鼠结肠癌细胞CT26黏附和迁移能力的影响[J]. 中医杂志, 2020, 61(13):1176-1183.
	WU X D, TANG D C. Effects of compatibility of Radix Astragali seu Hedysa and Rhizoma Curcumae on adhesion and migration ability of colon cancer cell CT26 in mice[J]. J Tradit Chin Med, 2020, 61(13):1176-1183. doi:10.13288/j.11-2166/r.2020.13.014.

组别	G1期	S期	G2期
对照组	37.82±0.29	43.16±0.88	19.05±0.60
低剂量组	36.12±0.25^a	46.33±0.33^a	17.54±0.10
中剂量组	38.27±0.73^b	47.57±0.74^a	14.16±1.03^ab
高剂量组	36.58±0.65^ac	50.39±1.63^abc	13.03±2.13^ab
F	11.230^＊＊	26.304^＊＊	15.896^＊＊

组别	G1期	S期	G2期
对照组	37.82±0.29	43.16±0.88	19.05±0.60
低剂量组	36.12±0.25^a	46.33±0.33^a	17.54±0.10
中剂量组	38.27±0.73^b	47.57±0.74^a	14.16±1.03^ab
高剂量组	36.58±0.65^ac	50.39±1.63^abc	13.03±2.13^ab
F	11.230^＊＊	26.304^＊＊	15.896^＊＊

组别	C-myc	CyclinD1
对照组	1.00±0.00	1.00±0.00
低剂量组	0.83±0.08^a	0.77±0.05^a
中剂量组	0.69±0.12^a	0.59±0.11^ab
高剂量组	0.54±0.09^ab	0.50±0.11^ab
F	16.339^＊＊	22.510^＊＊

组别	C-myc	CyclinD1
对照组	1.00±0.00	1.00±0.00
低剂量组	0.83±0.08^a	0.77±0.05^a
中剂量组	0.69±0.12^a	0.59±0.11^ab
高剂量组	0.54±0.09^ab	0.50±0.11^ab
F	16.339^＊＊	22.510^＊＊

组别	细胞凋亡率/%	Bax/Bcl-2	Caspase-3	Caspase-8
对照组	6.90±0.51	0.36±0.09	0.78±0.15	0.26±0.05
低剂量组	7.28±0.25	1.97±0.36^a	1.46±0.25^a	0.33±0.07
中剂量组	7.57±0.28	2.83±0.24^ab	1.53±0.14^a	0.45±0.09^a
高剂量组	11.06±0.37^abc	2.92±0.18^ab	1.89±0.17^abc	0.78±0.09^abc
F	83.244^＊＊	73.297^＊＊	19.353^＊＊	27.266^＊＊